Summary:
- The article discusses Iovance Biotherapeutics' clinical and commercial progress, specifically focusing on the performance of their FDA-approved tumor-infiltrating lymphocyte (TIL) therapy, Amtagvi.
- It highlights the company's transition from clinical development to commercialization, including operational milestones, revenue growth, and the strategic roadmap toward achieving corporate profitability.